Home
About us
Company Profile
Leader's Speech
Management team
Expert Consultant
development history
Research
R&D Platform
R&D Pipeline
R & D Field
News
Company News
Industry News
Recruit
Recruitment
Staff Style
Contact us
中文
Sitemaps
Home
Sitemaps
Home
About us
Company Profile
Leader's Speech
Management team
Expert Consultant
development history
Products
E-book
News
Company News
Katy Medicine and Shenghe Pharmaceuticals Sign Strategic Cooperation Agreement
Congratulations on the successful conclusion of the 2020 BPIT Biopharmaceutical Innovation Technology Conference
Nanjing Kati Medicine and Nanjing Children's Hospital held a GD2-CART cell therapy clinical research conference on childhood neuroblastoma
Dr. Enxiu Wang delivered a speech at the Symposium on Frontier Science and Innovative Therapy of Tumor Immunotherapy
Nanjing Kati Medical Technology Co., Ltd. won the first prize of the 2020 "Win in Nanjing Entrepreneurship Jinling" Technology Innovation and Entrepreneurship Competition
Wang Enxiu was selected as the “Entrepreneurship and Entrepreneurship Program” in 2020
Look at this first show! The special event of Jiangsu science and technology finance entering SMEs is coming
The patent examination expert group of the State Intellectual Property Office went to Nanjing Kati Medicine to conduct research
Hit it again! Kati won another National Natural Science Foundation project
Good news! Kati won the "Second Prize" in the "Entrepreneurship Jiangsu" competition
Good news! Nanjing Kati Medicine successfully passed the national high-tech enterprise certification
The 2020 Nanjing International Life and Health Technology Conference and Expo ended successfully!
Great news | Nanjing KATI's novel CAR-T Therapy is successful!
[First Release] KATI Medical completed the A+ round of financing of over 70 million ¥, and accelerated the IND application and pipeline development of leading products
Industry News
Development and challenges of "off-the-shelf" allogeneic CAR-T cells
The consensus of seven domestic and foreign institutions: CAR-T-induced CRS requires differentiated management methods, and consistent "grass-cutting" treatment may usher in new changes
FDA plans to publish CAR-T therapeutic product manufacturing guidelines
Contact us
Menu
Products
Contact us
Top